MARLBOROUGH, Mass.--(BUSINESS WIRE)--
Advanced Cell Technology, Inc. (“ACT”; OTCBB: ACTC), a leader in the field of regenerative medicine, announced today that the Wills Eye Institute in Philadelphia has received institutional review board (IRB) approval as a site for the company’s Phase I/II clinical trial for Stargardt’s Macular Dystrophy (SMD), a form of juvenile macular degeneration, using human embryonic stem cell (hESC)-derived retinal pigment epithelial (RPE) cells. Earlier this year, the Company also announced that the IRB at Wills Eye Institute had approved the participation of the institution as a site for ACT’s clinical trial for dry age-related macular degeneration (dry AMD).
“We thank Wills Eye Institute once more for providing their IRB and their invaluable contribution to our macular degeneration studies,” said Gary Rabin, ACT’s chairman and CEO. “We are very happy that we can now report that Wills Eye Institute has been approved as a clinical trial site for both our SMD and dry AMD clinical trials. Ranked as one of the best ophthalmology hospitals in the country by U.S. News & World Report, the Wills Eye Institute is a truly world-class institution. Our team is eagerly anticipating working with Dr. Carl Regillo, a renowned retinal surgeon and director of clinical retina research at Wills Eye Institute, as well as a professor of ophthalmology at Thomas Jefferson University, along with the rest of his team as we move forward with these ground-breaking trials.”
The Phase I/II trial for SMD is a prospective, open-label study designed to determine the safety and tolerability of the hESC-derived RPE cells following sub-retinal transplantation into patients with SMD. The trial will ultimately enroll 12 patients, with cohorts of three patients each in an ascending dosage format. Preliminary results relating to both early safety and biological function for the first two patients in the U.S., one SMD patient and one dry AMD patient, were recently reported in The Lancet.
Specific patient enrollment for both trials at the Wills Eye Institute will be determined in the near future. Further information about patient eligibility for the SMD study and the concurrent study on dry AMD is also available on http://www.clinicaltrials.gov; ClinicalTrials.gov Identifiers: NCT01345006 and NCT01344993.
About Stargardt's Disease
Stargardt’s disease or Stargardt’s Macular Dystrophy is a genetic disease that causes progressive vision loss, usually starting in children between 10 to 20 years of age. Eventually, blindness results from photoreceptor loss associated with degeneration in the pigmented layer of the retina, called the retinal pigment epithelium.
About hESC-derived RPE Cells
The retinal pigment epithelium (RPE) is a highly specialized tissue located between the choroids and the neural retina. RPE cells support, protect and provide nutrition for the light-sensitive photoreceptors. Human embryonic stem cells differentiate into any cell type, including RPE cells, and have a similar expression of RPE-specific genes compared to human RPE cells and demonstrate the full transition from the hESC state.
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc., is a biotechnology company applying cellular technology in the field of regenerative medicine. For more information, visit http://www.advancedcell.com.
About Wills Eye Institute
Wills Eye Institute is a global leader in ophthalmology, established in 1832 as the nation’s first hospital specializing in eye care. U.S. News & World Report has consistently ranked Wills Eye as one of America’s top three ophthalmology centers since the survey began in 1990. Wills Eye is a premier training site for all levels of medical education. Its resident and post-graduate training programs are among the most competitive in the country. One of the core strengths of Wills is the close connection between innovative research and advanced patient care. Wills provides the full range of primary and subspecialty eye care for improving and preserving sight, including cataract, cornea, retina, emergency care, glaucoma, neuro-ophthalmology, ocular oncology, oculoplastics, pathology, pediatric ophthalmology and ocular genetics, refractive surgery and retina. Ocular Services include the Wills Laser Correction Center, Low Vision Service, and Diagnostic Center. Its 24/7 Emergency Service is the only one of its kind in the region. Wills Eye also has a network of nine multi-specialty, ambulatory surgery centers throughout the tri-state area. To learn more, please visit http://www.willseye.org.
Forward-Looking Statements
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates,” and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company’s periodic reports, including the report on Form 10-K for the year ended December 31, 2010. Forward-looking statements are based on the beliefs, opinions, and expectations of the company’s management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change. Forward-looking statements are based on the beliefs, opinions, and expectations of the company’s management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change. There can be no assurance that the Company’s clinical trials will be successful.
Go here to read the rest:
Advanced Cell Technology Announces Approval of Wills Eye Institute as Additional Site for Stem Cell Clinical Trial for ...
- Elton John unsure if he can return to work after severe infection caused loss of vision in right eye - Fox News - November 27th, 2024
- Elton John Reveals He Lost Vision in His Right Eye from an Infection: 'Floored Me' - PEOPLE - November 27th, 2024
- Elton John reveals he cant see anything in his right eye after infection - The Independent - November 27th, 2024
- Elton John reveals hes blind in his right eye after infection: I cant see anything - New York Post - November 27th, 2024
- Elton John reveals he's 'lost his eyesight in his right eye' following a 'severe eye infection' - 9Honey Celebrity - November 27th, 2024
- Elton John says he has lost sight in one eye after infection - WKRN News 2 - November 27th, 2024
- Sir Elton John, 77, admits he was 'floored' by losing his vision in one eye as he admits he is 'stuck' and una - Daily Mail - November 27th, 2024
- Elton John shares he's lost vision in his right eye after infection - NBC Connecticut - November 27th, 2024
- Elton John battles vision loss after summer infection, shares update on health - The Mirror US - November 27th, 2024
- Elton John Speaks Out About Lost of Sight Due to Infection - 102.9 WMGK - November 27th, 2024
- Elton John has gives an update on vision problems - Yahoo News UK - November 27th, 2024
- Elton John gives an update on vision problems - Yahoo News UK - November 27th, 2024
- Elton John Has Lost Vision In His Right Eye Following Infection - iHeart - November 27th, 2024
- One in three children affected by myopia: How early detection and care can protect their vision - The Times of India - November 27th, 2024
- Test your eyesight: Only a person with perfect vision can spot a mug of milk in 10 seconds - The Times of India - November 27th, 2024
- Elton John reveals he went blind in his right eye saying I cant see anything. I cant read anything... - The Sun - November 27th, 2024
- $6 million grant drives potential treatment for common cause of vision loss toward the clinic - University of Southern California - November 27th, 2024
- Silent Struggles: Addressing the Growing Threat of Diabetes-Induced Vision Loss - ETHealthWorld - November 27th, 2024
- Seeing Is Believing: The Gene Therapy Breakthrough Thats Giving Sight to the Blind - SciTechDaily - September 21st, 2024
- VisiActive Review: The Natural Approach to Enhancing Your Vision and Eye Care - Bellevue Reporter - September 21st, 2024
- Does VisiActive Work? An Honest Review of Its Eye Health Claims - Kirkland Reporter - September 21st, 2024
- Sharp eye test: Only those with a perfect vision can spot the third dog in the picture - The Times of India - September 21st, 2024
- Does X Vision Really Work? An Honest Review of Its Eye Health Benefits - Islands' Sounder - September 21st, 2024
- VisiActive Review: Is This the Ultimate Supplement for Clearer, Healthier Vision? - Vashon-Maury Island Beachcomber - September 21st, 2024
- New Report Recommends Myopia Be Classified as a Disease, Policies for Children to Spend Time Outdoors - National Academies of Sciences, Engineering,... - September 21st, 2024
- X Vision Review: How Effective Is This Supplement for Enhancing Vision and Eye Health? - Kirkland Reporter - September 21st, 2024
- Elon Musk's Neuralink is working on a product called Blindsight that can restore vision: story in 5 points - India Today - September 21st, 2024
- How the eyes are windows into our health and why we should get them tested - South China Morning Post - September 21st, 2024
- UK research finds lower rate of GOS sight test activity in areas of deprivation - AOP - September 21st, 2024
- Dudley residents urged to keep an eye on their optic health - Dudley News - September 21st, 2024
- Test your eyesight: Find the odd red plane in under 7 seconds - The Times of India - August 7th, 2024
- You have 20/20 vision if you can find the hidden chick amongst these ducks - IndiaTimes - December 30th, 2023
- How to watch the solar eclipse without damaging your eyesight - WATE 6 On Your Side - October 16th, 2023
- Can Optical Illusions Improve Vision? Know The Best One That Benefits Eyesight - Times Now - May 17th, 2023
- Motus GI Announces Executive Leadership Restructuring and Additional Cost Saving Initiatives to Support Near-Term Milestones - April 15th, 2023
- Revolution Medicines to Participate in 22nd Annual Needham Healthcare Conference - April 15th, 2023
- GENFIT Reports Full-Year 2022 Financial Results and Provides Corporate Update - April 15th, 2023
- Kane Biotech to Release Fourth Quarter and Full Year 2022 Financial Results on April 20, 2023 – Conference Call to Follow - April 15th, 2023
- Biomea Fusion To Present Two Preclinical Posters at the 114th AACR Annual Meeting - April 15th, 2023
- Cabaletta Bio to Present at the 22nd Annual Needham Virtual Healthcare Conference - April 15th, 2023
- Syneos Health Schedules First Quarter 2023 Earnings Call for Wednesday, May 10th, 2023 - April 15th, 2023
- Oncternal Therapeutics Participating in Oppenheimer & Co.’s Virtual Fireside Chat: Discussion of ROR1 CAR T Cell Therapy in Hematological... - April 15th, 2023
- Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - April 15th, 2023
- Alvotech Provides Regulatory Update on AVT02 Biologics License Application - April 15th, 2023
- Vivoryon Therapeutics N.V. to Report Full Year 2022 Financial Results and Operational Progress on April 19, 2023 - April 15th, 2023
- Additional Future Royalty Revenue Stream for Nicox from 2024 following New Drug Application Submission for ZERVIATE in China - April 15th, 2023
- Ultimovacs ASA – Disclosure of voting rights of Annual General Meeting - April 15th, 2023
- QIAGEN showcases latest technologies to advance cancer research at AACR Annual Meeting 2023 - April 15th, 2023
- ITM lädt zu Symposium und Messestand auf der Jahrestagung der Deutschen Gesellschaft für Nuklearmedizin in Leipzig ein - April 15th, 2023
- International Carrot Day: From healthy eyesight to weight loss - 5 wonderful benefits of carrot - Zee Business - April 7th, 2023
- How the Human Eye Works | Cornea Layers/Role | Light Rays - NKCF.org - December 11th, 2022
- Eye Emergencies: Types, Symptoms, and Prevention - Healthline - November 25th, 2022
- The criteria for certification | RNIB - November 25th, 2022
- Foresight: Eye-Net Successfully Showcases its Advanced Solution to Leading OEMs and Tier One Suppliers in Japan - Marketscreener.com - November 25th, 2022
- Can you see me now? Average person begins worrying about their vision at age 39 - Study Finds - September 29th, 2022
- Contact lens wearers at higher risk of rare eye infection are you caring for your lenses the right way? - News24 - September 29th, 2022
- A man who popped a champagne cork into his eye says it felt like being poked 'times a thousand.' His vision was saved after months of treatment but it... - September 29th, 2022
- Whitsett Vision Group First to Use Revolutionary New Lens to Dramatically Improve Patients' Eyesight - PR Newswire - September 29th, 2022
- 'As one door closes, another opens': Adelaide man turned to yoga, meditation after major vision loss - SBS - September 29th, 2022
- Stephen Curry, whose $185,000 worth vehicle almost took his life, is sure to lose his eyesight due to a genetic defect - The Sportsrush - September 29th, 2022
- NCCVEH Names Dr. Donny W. Suh, Gavin Herbert Eye Institute, UC Irvine, as Recipient of the 8th Annual Bonnie Strickland Champion for Children's Vision... - September 29th, 2022
- XP Health Raises $17.1M Series A to Transform Vision Benefits for Insurance Carriers, Companies and Employees - PR Web - September 29th, 2022
- Everything You Need To Know About Ocular Herpes Zoster: Symptoms, Treatment, And Complications - World Nation News - September 29th, 2022
- Blurry vision turned out be tumour behind Exeter woman's eye - Devon Live - April 26th, 2022
- Woman who lost half her body weight sheds the stones for second time after sight loss - Yahoo News - April 26th, 2022
- High Schooler's Nausea Turned Out To Be Aggressive and Deadly Brain Tumor - Newsweek - April 26th, 2022
- BattleVision Storm Glasses Sees Uptick in Sales as Winter Hits - Benzinga - Benzinga - January 1st, 2022
- Insights on the Eye Care Surgical Global Market to 2026 - Featuring Abbott Laboratories, Alcon Vision and Avedro Among Others - PRNewswire - January 1st, 2022
- Monocular vision (sight in one eye) - RNIB - See differently - November 21st, 2021
- See which of your habits is actually hurting your eyesight - Yahoo News UK - November 21st, 2021
- CVRS, TEH protect the gift of sight with free eye surgeries | Loop Trinidad & Tobago - Loop News Trinidad and Tobago - November 21st, 2021
- Take More Walking to Improve Your Eyesight! - Central Recorder - November 21st, 2021
- Remedies to reduce eye strain while working from home - The Siasat Daily - November 21st, 2021
- Chris McCausland: 'I was diagnosed with retinitis pigmentosa' what is that? - Daily Express - November 21st, 2021
- 5th Graders help Pittsburg Lions Club improve vision for those in need Newstalk KZRG - newstalkkzrg.com - November 21st, 2021
- Uptick in vision problems among children could be due to screen time - Wink News - November 21st, 2021
- Lindsay Senior With Worsening Eyesight Urges Government And Optometrists To Resume OHIP Eye Care - Kawartha 411 - November 21st, 2021
- The Link Between Loneliness and Vision Impairment on Dementia - DocWire News - November 21st, 2021
- Optometrist warns of the long-term effects drinking can have on your eyes - Daily Express - November 21st, 2021
- Horizon Therapeutics Recognizes Second Annual Thyroid Eye Disease (TED) Awareness Week with New Educational and Community Building Initiative -... - November 21st, 2021